In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals (ATNM - Research Report), with a price target of $53.00. The company's shares opened today at $13.10.Pantginis covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, PDS Biotechnology, and Palatin Technologies. According to TipRanks, Pantginis has an average return of -17.2% and a 29.38% success rate on recommended stocks. Currently, the analyst consensus on Actinium Pharmaceuticals is a Strong Buy with an average price target of $30.00, a 129.01% upside from current levels.
https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-actinium-pharmaceuticals-atnm?utm_source=advfn.com&utm_medium=referral
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Jan 2023 à Fév 2023 Plus de graphiques de la Bourse Actinium Pharmaceuticals
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Fév 2022 à Fév 2023 Plus de graphiques de la Bourse Actinium Pharmaceuticals